Stingthera has signed a clinical trial collaboration agreement with Merck to analyse the combination of investigational SNX281 and Keytruda (pembrolizumab) in some patients with advanced solid tumours and lymphoma.
AbbVie is set to acquire Teneobio affiliate TeneoOne and its lead drug candidate TNB-383B, which is being developed to treat relapsed or refractory multiple myeloma (R/R MM).
GlaxoSmithKline (GSK) and iTeos Therapeutics have signed an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody presently under phase I development as a potential treatment for cancer patients.
Bristol-Myers Squibb (BMS) has agreed to obtain a worldwide exclusive licence to a cancer antibody programme, AGEN1777, and a second undisclosed target developed by immuno-oncology firm Agenus.
Dr. Reddy's Laboratories has signed an agreement with Shenzhen Pregene Biopharma to acquire an exclusive license in India for PRG1801, Pregene's single domain antibody-based anti-BCMA chimeric antigen receptor T (CAR-T) cell therapy injection.
The second indication of Sarclisa (isatuximab) for the treatment of adult patients with relapsed multiple myeloma, was approved by the European Commission (EC).
Gilead Sciences has announced the accelerated approval of Trodelvy (or sacituzumab govitecan-hziy) by the US Food and Drug Administration (FDA) in the treatment of locally advanced or metastatic urothelial cancer (UC) in adult patients.
Global biopharmaceutical company Sanofi has acquired privately owned, pre-clinical stage biotech company Tidal Therapeutics, which brings with it an mRNA-based approach for in vivo (inside the body) reprogramming of immune cells.
Biotechnology company Anixa Biosciences, partnered by IT and pharma solutions company OntoChem, has announced that it will enter the next stage of development of its potential anti-viral therapy for Covid-19.
Merck has announced that the US Food and Drug Administration (FDA) has sent a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) for the approval of KEYTRUDA.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.